Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins
Massimiliano Mirolo1,*, Marco Fabbri1,*, Marina Sironi1,*, Annunciata Vecchi2, Angelo Guglielmotti3, Giorgina Mangano3, Giuseppe Biondi3, Massimo Locati1,4, Alberto Mantovani1,4
European Cytokine Network, Vol.19, No.3, pp. 119-122, 2008, DOI:10.1684/ecn.2008.0133
Abstract Bindarit is an indazolic derivative that is devoid of any immunosuppressive effects and has no effect
on arachidonic acid metabolism. However, it has been proved to have anti-inflammatory activity in a number of
experimental diseases, including pancreatitis, arthritis, and lupus nephritis. This therapeutic effect has been
associated with its ability to interfere selectively with monocyte recruitment, although the underlying molecular
mechanisms are unknown. Here we comprehensively examine the effect of bindarit on the chemokine system, and
report that in activated monocytes and endothelial cells, it selectively inhibits the production of the monocyte
chemotactic protein subfamily More >